Retevmo
E561040
Retevmo is a targeted cancer therapy (selpercatinib) used to treat tumors driven by RET gene alterations, including certain lung and thyroid cancers.
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
pharmaceutical drug
ⓘ
targeted cancer therapy ⓘ tyrosine kinase inhibitor ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| approvedIn |
European Union
NERFINISHED
ⓘ
Japan NERFINISHED ⓘ United States NERFINISHED ⓘ |
| belongsToPharmacologicClass | selective RET inhibitor ⓘ |
| contraindicatedWith | severe hypersensitivity to selpercatinib ⓘ |
| developedBy | Eli Lilly and Company NERFINISHED ⓘ |
| hasActiveIngredient | selpercatinib ⓘ |
| hasApprovalType | FDA accelerated approval ⓘ |
| hasATCCode | L01EX19 ⓘ |
| hasBlackBoxWarning | hepatotoxicity ⓘ |
| hasCommonAdverseEffect |
constipation
ⓘ
diarrhea ⓘ dry mouth ⓘ edema ⓘ elevated liver enzymes ⓘ fatigue ⓘ hypertension ⓘ |
| hasDosageForm | capsule ⓘ |
| hasDrugInteraction |
strong CYP3A inducers
ⓘ
strong CYP3A inhibitors ⓘ |
| hasHalfLife | approximately 32 hours ⓘ |
| hasInternationalNonproprietaryName | selpercatinib NERFINISHED ⓘ |
| hasPregnancyRisk | may cause fetal harm ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasWarning |
QT interval prolongation
ⓘ
hemorrhagic events ⓘ hypersensitivity reactions ⓘ hypertension ⓘ risk of impaired wound healing ⓘ |
| indicatedFor |
RET fusion-positive non-small cell lung cancer
ⓘ
RET fusion-positive thyroid cancer ⓘ RET-mutant medullary thyroid cancer ⓘ advanced RET fusion-positive thyroid carcinoma ⓘ advanced medullary thyroid carcinoma with RET mutation ⓘ metastatic non-small cell lung cancer with RET gene fusion ⓘ |
| mechanismOfAction | selective RET kinase inhibition ⓘ |
| metabolizedBy | CYP3A4 NERFINISHED ⓘ |
| regulatesPathway | RET signaling pathway ⓘ |
| requiresCompanionDiagnostic | RET gene alteration testing ⓘ |
| targetsGene | RET ⓘ |
| usedIn |
adult patients
ⓘ
pediatric patients 12 years and older ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Loxo Oncology